Abstract Library

#4492 Utility of NETest 2.0 as a biomarker for neuroendocrine tumours: The Swiss experience – Real-world data

Introduction: The NETest 2.0 is a PCR assay of circulating mRNA, scored 0-100. It has been developed as a biomarker to diagnose neuroendocrine neoplasia (NEN) and to provide tumour prognostic information.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, NEN, disease presence, disease progression,

#3609 Interest of systematic resection of the visible scar, after incomplete endoscopic resection of rectal neuroendocrine tumors

Introduction: Rectal Neuroendocrine tumors (r-NET) can often be misidentified as diminutive polyps, leading to inappropriate resection technique. When the initial resection is not R0, the persistence of a local residue could lead to a disease recurrence.

Conference:

Presenting Author:

Authors: Cheminel L, Wallenhorst T, Lepilliez V, Jacques J, Abou Ali E,

Keywords: rectal neuroendocrine tumor, incomplete resection, endoscopy, salvage resection,

#3338 Utility of SSTR radioligands in imaging and treatment of paediatric GEP-NETs

Introduction: Metastasized gastroenteropancreatic neuroendocrine tumors (GEP-NETS) in paediatric patients

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Steyn R

Authors: Steyn R, Kolade O, Aldera A, Masoka B, Radebe B,

Keywords: SSTR, PRRT, paediatric, GEP-NET,

#3334 Utility of midpoint imaging in patients receiving peptide receptor radionuclide therapy (PRRT) for advanced progressive midgut neuroendocrine tumors (NET)

Introduction: The NETTER-1 trial formed the basis for standard practice of PRRT, consisting of 4 cycles with follow-up imaging during midtreatment and after completion to evaluate disease response. However, in clinical practice the timing of midpoint imaging varies if performed at all, and it is unclear how often it influences subsequent management.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Norman A, Wee C, Hobday T, Kendi A, Johnson G,

Keywords: midpoint imaging, PRRT, clinical decision making,

#3287 Utilization of next generation sequencing in NET/NEC management and practice patterns: A prospective survey of global NET specialists

Introduction: Next generation sequencing based somatic tumor mutation as well as germline mutation data is being increasingly used in cancer management. Pan tumor type FDA approval for NTRK fusion, intermediated-high tumor mutation burden and MSI high status has paved way for tissue agnostic molecularly targeted therapies. Utilization of NGS in neuroendocrine tumor (NET) and neuroendocrine carcinoma (NEC) is currently unknown.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Chauhan A, Munir A, Hernando J, Leeuwaarde R, Zhang P,

Keywords: NGS, NEC, NET,